NorthWest Biotherapeutics Inc (NWBO)

[Gus McCrae]

Publishing is much more meaningful, has broader reach and is more permanent as a means of communicating the information than a presentation to a random room of doctors attending a conference.

So now you are an expert on how to launch a drug too? You realize the person that you are responding to is an actual subject matter expert, right? And yet you authoritatively insist that he is wrong and you are right regarding a subject you know nothing about?

Presenting at a conference does NOT preclude the publication of the full trial results in a medical journal. There are THOUSANDS of examples of published articles that include information that was previously presented at a conference. If DCVAX-L is going to be the new SOC for GBM...journals will be lining up to publish the full trial results, regardless of whether some of that information was presented at a medical conference. You know this, right? This is literally how every other publicly traded biotech in the United States does this.

Again, this is the first time in history that a biotech has withheld TLD in anticipation of publishing the full trial results in a journal. THE VERY FIRST TIME!!! So how can you know whether it is a better way, or the best way, to release TLD?

And I will also say this again...I believe the company is lying to us when they say the delay in TLD is because they are waiting on publishing, for all of the reasons set forth above. There is something else going on.